Your browser doesn't support javascript.
loading
BET inhibition as a new strategy for the treatment of gastric cancer.
Montenegro, Raquel C; Clark, Peter G K; Howarth, Alison; Wan, Xiao; Ceroni, Alessandro; Siejka, Paulina; Nunez-Alonso, Graciela A; Monteiro, Octovia; Rogers, Catherine; Gamble, Vicki; Burbano, Rommel; Brennan, Paul E; Tallant, Cynthia; Ebner, Daniel; Fedorov, Oleg; O'Neill, Eric; Knapp, Stefan; Dixon, Darren; Müller, Susanne.
Afiliação
  • Montenegro RC; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
  • Clark PG; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Howarth A; Federal University of Pará, Institute of Biological Sciences, Belém, Pará 66075-110, Brazil.
  • Wan X; Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, UK.
  • Ceroni A; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Siejka P; CRUK/MRC Oxford Institute of Radiation Biology, University of Oxford, Headington OX3 7DQ, UK.
  • Nunez-Alonso GA; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Monteiro O; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
  • Rogers C; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Gamble V; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
  • Burbano R; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Brennan PE; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
  • Tallant C; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Ebner D; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
  • Fedorov O; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • O'Neill E; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
  • Knapp S; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK.
  • Dixon D; Federal University of Pará, Institute of Biological Sciences, Belém, Pará 66075-110, Brazil.
  • Müller S; The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.
Oncotarget ; 7(28): 43997-44012, 2016 Jul 12.
Article em En | MEDLINE | ID: mdl-27259267
ABSTRACT
Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to the development and progression of this malignancy. In order to explore new treatment options in this target area we have screened a library of epigenetic inhibitors against gastric cancer cell lines and identified inhibitors for the BET family of bromodomains as potent inhibitors of gastric cancer cell proliferations. Here we show that both the pan-BET inhibitor (+)-JQ1 as well as a newly developed specific isoxazole inhibitor, PNZ5, showed potent inhibition of gastric cancer cell growth. Intriguingly, we found differences in the antiproliferative response between gastric cancer cells tested derived from Brazilian patients as compared to those from Asian patients, the latter being largely resistant to BET inhibition. As BET inhibitors are entering clinical trials these findings provide the first starting point for future therapies targeting gastric cancer.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azepinas / Fatores de Transcrição / Triazóis / Proteínas Nucleares / Proliferação de Células / Isoxazóis Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azepinas / Fatores de Transcrição / Triazóis / Proteínas Nucleares / Proliferação de Células / Isoxazóis Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2016 Tipo de documento: Article